Comparison between three oxaliplatin-based regimens with bevacizumab in patients with metastatic colorectal cancer

BACKGROUND: A previous pivotal Phase III study (NO16966) demonstrated the benefit of the addition of bevacizumab (BV) to oxaliplatin-based regimens in metastatic colorectal cancer (MCRC). Our study evaluated the safety and efficacy of three oxaliplatin-based chemotherapy regimens (FOLFOX4 [intraveno...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Onco Targets Ther
Hlavní autoři: Ohhara, Yoshihito, Suenaga, Mitsukuni, Matsusaka, Satoshi, Shinozaki, Eiji, Mizunuma, Nobuyuki, Yamaguchi, Toshiharu
Médium: Artigo
Jazyk:Inglês
Vydáno: Dove Medical Press 2015
Témata:
Original Research
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4354450/
https://ncbi.nlm.nih.gov/pubmed/25767397
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S77190
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky